Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Appointment of Ms. Susan Knight and Mr. Stephen Denaro to the Board of Directors
-
Anteris Announces Results for the First Quarter of 2026
-
Anteris Technologies Announces the First U.S. Patients Treated in the Global Pivotal PARADIGM Trial
-
Anteris Technologies secures CMS reimbursement supporting U.S. site activation for the global pivotal PARADIGM Trial evaluating the DurAVR THV
-
Anteris Reports 2025 Financial Results and Provides Corporate Update
-
Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
-
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
-
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
-
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company...
-
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company...